Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial

被引:0
作者
Jinming Shi
Ning Li
Yuan Tang
Liming Jiang
Lin Yang
Shulian Wang
Yongwen Song
Yueping Liu
Hui Fang
Ningning Lu
Shunan Qi
Bo Chen
Ziyu Li
Shixin Liu
Jun Wang
Wenling Wang
Suyu Zhu
Jialin Yang
Yexiong Li
Dongbing Zhao
Jing Jin
机构
[1] National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital,Department of Radiation Oncology
[2] Chinese Academy of Medical Sciences and Peking Union Medical College,State Key Laboratory of Molecular Oncology and Department of Radiology
[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,State Key Laboratory of Molecular Oncology and Department of Medical Oncology
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology
[5] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Radiation Oncology
[6] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Radiation Oncology
[7] Peking University Cancer Hospital and Institute,Department of Radiation Oncology
[8] Jilin Provincial Cancer Hospital,Department of Radiation Oncology
[9] Hebei Provincial Cancer Hospital,Department of Radiation Oncology
[10] Guizhou Provincial Cancer Hospital,Department of Pancreatic and Gastric Surgery
[11] Hunan Cancer Hospital and Affiliated Cancer Hospital of Xiangya School of Medicine,Department of Radiation Oncology
[12] Sichuan Provincial Cancer Hospital,undefined
[13] National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital,undefined
[14] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
[15] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital,undefined
[16] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
来源
BMC Gastroenterology | / 22卷
关键词
Locally advanced; Gastric cancer; Esophagogastric junction adenocarcinoma; Neoadjuvant chemoradiotherapy; Consolidated chemotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 106 条
[1]  
Colquhoun A(2015)Global patterns of cardia and non-cardia gastric cancer incidence in 2012 Gut 64 1881-1888
[2]  
Arnold M(2016)Cancer statistics in China, 2015 CA: Cancer J Clin 66 115-132
[3]  
Ferlay J(2016)The patterns and timing of recurrence after curative resection for gastric cancer in China World J Surg Oncol 14 305-316
[4]  
Chen W(2012)Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection J Clin Oncol 30 2327-2333
[5]  
Zheng R(2020)A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Ann Oncol 09 503-515
[6]  
Baade PD(2018)Preoperative conformal radiotherapy concurrently with paclitaxel/carboplatin in gastric cancer J Cancer Ther 16 1090-1098
[7]  
Liu D(2015)Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial Lancet Oncol 393 1948-1957
[8]  
Lu M(2019)Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Lancet 355 11-20
[9]  
Li J(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 29 1715-1721
[10]  
Smalley SR(2011)Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial J Clin Oncol 19 616-628